Stevanato Group SpA (N:STVN)

Business Focus: Medical Equipment, Supplies & Distribution

Get the company report for the most recent outlook updated daily

May 09, 2024 06:39 am ET

Stevanato Group Reports Financial Results for the First Quarter of 2024

Apr 04, 2024 08:00 am ET

Stevanato Group appoints Ugo Gay as Chief Operations Officer

Mar 26, 2024 04:10 pm ET

Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares

Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the underwriters’ option to purchase 1,905,000 additional ordinary shares, at a public offering price of $26.00 per share.

Mar 21, 2024 11:45 pm ET

Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares

Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.

Mar 20, 2024 05:12 pm ET

Stevanato Group Announces Public Offering of Ordinary Shares

Mar 11, 2024 05:05 pm ET

Stevanato Group to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum taking place from Tuesday, March 19, 2024 to Wednesday, March 20, 2024.

Mar 07, 2024 06:30 am ET

Stevanato Group Delivers Double-Digit Revenue Growth in Fiscal Year 2023

Feb 22, 2024 04:30 pm ET

Stevanato Group to Report Fourth Quarter and Year End 2023 Financial Results on March 7, 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET).

Jan 24, 2024 08:00 am ET

Stevanato Group Launches EZ-fill® Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, unveiled today two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Techn

Jan 03, 2024 04:30 pm ET

Stevanato Group to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8, 2024 to January 11, 2024 in San Francisco, California.

Nov 16, 2023 06:00 am ET

Stevanato Group's Mavis™ Combi Visual Inspection Machine Selected as Pharma Innovation Award Winner by Pharma Manufacturing

Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, announced today that its Mavis™ Combi visual inspection machine has been selected as a winner of the 2023 Pharma Innovation Awards by Pharma Manufacturing, a brand of Endeavor

Nov 09, 2023 06:30 am ET

Stevanato Group to Present at the Jefferies London Healthcare Conference

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Jefferies London Healthcare Conference taking place from November 14, 2023 to November 16, 2023.

Oct 31, 2023 06:30 am ET

Stevanato Group Reports Third Quarter 2023 Financial Results

Oct 17, 2023 04:05 pm ET

Stevanato Group to Report Third Quarter 2023 Financial Results on October 31, 2023

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2023 on Tuesday, October 31, 2023, at 6:30 a.m. (ET).

Oct 05, 2023 04:05 pm ET

Stevanato Group Announces Voting Results from its Extraordinary General Meeting

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that the resolution proposed to shareholders at the Extraordinary General Meeting of Shareholders (“EGM”) held virtually on October 4, 2023 was passed.

Sep 19, 2023 04:07 pm ET

Stevanato Group to Livestream Inaugural Capital Markets Day on September 27, 2023

Jul 28, 2023 06:30 am ET

Stevanato Group Reports Second Quarter 2023 Financial Results

Jul 14, 2023 04:05 pm ET

Stevanato Group to Report Second Quarter 2023 Financial Results on July 28, 2023

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2023 on Friday, July 28, 2023, at 6:30 a.m. (ET).

Jun 12, 2023 08:00 am ET

Stevanato Group Presents Vertiva™, a Versatile On-Body Delivery System Platform for a Wide Range of Injectable Therapies and for Large Delivery Volumes (up to 10mL)

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled today Vertiva™, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suit

Jun 07, 2023 12:30 pm ET

Stevanato Group Announces Change in Ex-Dividend Date for its Dividend

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with New York Stock Exchange rules. The new ex-dividend date for the dividend will be June 7, 2023, and the record date remains June 6, 2023. The dividend will continue to be payable on July 17, 2023.

May 24, 2023 04:01 pm ET

Stevanato Group to Present at Upcoming Investor Conferences

May 04, 2023 06:31 am ET

Stevanato Group Reports First Quarter 2023 Financial Results

May 02, 2023 06:30 am ET

Stevanato Group to Present at BofA Securities Healthcare Conference

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the upcoming BofA Securities Healthcare Conference at the Encore hotel in Las Vegas that will take place from May 9, 2023 to May 11, 2023.

Apr 17, 2023 04:30 pm ET

Stevanato Group to Report First Quarter 2023 Financial Results on May 4, 2023

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m. (ET).

Mar 21, 2023 06:30 am ET

Stevanato Group Collaborates with Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to Market

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today its collaboration with

Mar 16, 2023 08:00 am ET

Stevanato Group Collaborates with Recipharm to Develop and Manufacture Pre-fillable Syringes for Use in a New Soft Mist Inhaler for the Inhalation of Sensitive Biological Products

Mar 14, 2023 06:00 am ET

Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum taking place on March 21 and March 22, 2023.

Mar 08, 2023 12:30 pm ET

Stevanato Group Secures €130 Million ESG-Linked Financing From BNL BNP Paribas and Cassa Depositi e Prestiti to Support Sustainable Global Growth

Mar 02, 2023 06:30 am ET

Stevanato Group Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Feb 16, 2023 04:45 pm ET

Stevanato Group to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 2, 2023

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2022 on Thursday, March 2, 2023, at 6:30 a.m. (ET).

Jan 24, 2023 08:00 am ET

Stevanato Group Collaborates with Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma

Nov 10, 2022 04:01 pm ET

Stevanato Group to Present at Upcoming Investor Conference

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that management will present at the Jefferies London Healthcare Conference at 12:55 p.m. (GMT) on November 17, 2022.

Nov 08, 2022 06:30 am ET

Stevanato Group Reports Third Quarter 2022 Financial Results

Nov 01, 2022 11:23 am ET

Stevanato Group and Gerresheimer AG Present EZ-fill Smart™, a New and Innovative Ready-To-Use Vial Platform

Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and

Oct 27, 2022 08:01 am ET

Stevanato Group and DWK Life Sciences Sign Non-Exclusive Distribution Agreement for EZ-fill® Platform Products

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, and

Oct 24, 2022 04:05 pm ET

Stevanato Group to Report Third Quarter 2022 Financial Results on November 8, 2022

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2022 on Tuesday, November 8, 2022, at 6:30 a.m. (ET).

Oct 19, 2022 07:26 pm ET

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.

Sep 09, 2022 09:00 am ET

Stevanato Group to Present at Upcoming Investor Conference

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that management will present at the Bank of America Global Healthcare Conference in London at 9:05 a.m. (BST) on September 15, 2022.

Sep 07, 2022 06:00 am ET

Stevanato Group and Gerresheimer AG Announce Collaboration on the Development of an Innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry

Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics, announce that they have jointly developed a high-end Ready-To-Use (RTU) solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology. This collaboration is projected to help customers gain efficiencies, improve the quality standard, inc

Aug 04, 2022 06:29 am ET

Stevanato Group Reports Second Quarter 2022 Financial Results

Jul 22, 2022 04:03 pm ET

Stevanato Group to Report Second Quarter 2022 Financial Results on August 4, 2022

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2022 on Thursday, August 4, 2022, at 6:30 a.m. (EST).

Jun 13, 2022 08:00 am ET

Stevanato Group Releases Sustainability Report 2021, Highlighting the Environmental, Social and Governance (ESG) Performance of the Group

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announces the publication of its Sustainability Report 2021. The report showcases the Group’s holistic approach to sustainable development and highlighted strong guidance aimed at pursuing goals pertaining to economic sustainability, its responsibility to innovation and new products, employees, and the environment.

Jun 02, 2022 04:05 pm ET

Stevanato Group Announces Voting Results from its Annual General Meeting

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that all resolutions proposed to Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on June 1, 2022 were passed.

Jun 01, 2022 04:59 pm ET

Stevanato Group to Present at Upcoming Investor Conferences

May 31, 2022 04:01 pm ET

Stevanato Group Adding New Capacity in Italy Amid Growing Demand for Its Market-Leading Solutions

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced the acquisition of a new industrial complex in Cisterna di Latina, Italy. The new facility is expected to strengthen Stevanato Group’s presence in Europe and expand the Company’s production capabilities to satisfy increased demand for its standard and premium products from high-growth customers.

May 10, 2022 06:30 am ET

Stevanato Group Reports First Quarter 2022 Financial Results

May 06, 2022 04:05 pm ET

Stevanato Group Publishes Materials for 2022 Annual General Meeting

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it has published the agenda for the 2022 Annual General Meeting of Shareholders (“AGM”), which will be held virtually on June 1, 2022, beginning at 4:00 p.m. (CEST) / 10:00 a.m. (EDT).

May 04, 2022 09:00 am ET

Stevanato Group and Owen Mumford Sign Exclusive Collaboration Agreement for the Innovative Aidaptus® Auto-Injector

Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus® auto-injector.

Apr 29, 2022 09:00 am ET

Stevanato Group S.p.A. and Bexson Biomedical, Inc. Expand Collaboration to Treat a Range of Mental Health Conditions With an On-body Device

Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Bexson Biomedical, Inc., a research stage company developing subcutaneous therapies for pain management and mental health disorders, announced today that they have signed an agreement expanding their collaboration.

Apr 27, 2022 07:50 am ET

Stevanato Group to Report First Quarter 2022 Financial Results on May 10, 2022

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the first quarter of 2022 on Tuesday, May 10, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time).

Apr 05, 2022 08:30 am ET

Stevanato Group Files Amendment No.1 to Its 2021 Annual Report on Form 20‑F/A

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced the filing of Amendment No. 1 (the “Form 20-F/A”) to its 2021 Annual Report on Form 20-F (the “Form 20-F”), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 8, 2022, to submit the Interactive Data File and to provide certain additional information as described in the explanatory note thereto.

Mar 17, 2022 04:30 pm ET

Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Management will present virtually at 9:00 a.m. EDT on Tuesday, March 22, 2022.

Mar 10, 2022 08:30 am ET

Stevanato Group to Create Manufacturing Hub in China

Stevanato Group (NYSE: STVN) (the “Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the acquisition of a facility in Zhangjiagang for a new plant where the Company expects to begin renovations in the spring 2022, as part of the latest phase of its expansion in China.

Mar 08, 2022 06:30 am ET

Stevanato Group Reports Record 2021 Revenue of €843.9 million

Mar 01, 2022 08:30 am ET

Stevanato Group Announces Agreement With BARDA for the Expansion of Vial Production to Create Industrial Base Capabilities for National Defense

Stevanato Group (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its subsidiary, OMPI of America Inc., entered into an agreement to support the Biomedical Advanced Research and Development Authority (“BARDA”, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services through its partnership with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and N

Feb 18, 2022 08:30 am ET

Stevanato Group to Report Fourth Quarter Financial Results on March 8, 2022

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the fourth quarter and full year of fiscal year 2021 on Tuesday, March 8, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time).

Feb 02, 2022 08:30 am ET

Stevanato Group Appoints Riccardo Butta as President, Americas

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas.

Jan 26, 2022 08:00 am ET

Stevanato Group Extends Pen Injector Technology Licensing Agreement With Haselmeier

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has signed an extension to its licensing agreement with Haselmeier, a company of the medmix group, for its Axis-D™ pen injector technology.

Nov 17, 2021 09:30 am ET

Stevanato Group Announces Expansion of Corporate Headquarters

Stevanato Group (NYSE: STVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the expansion of its corporate headquarters with the construction of a new facility in Piombino Dese, Italy to advance operations and growth of the Company.

Nov 09, 2021 06:30 am ET

Stevanato Group Reports Strong Third Quarter 2021 Revenue and Financial Results and Updates Full Year 2021 Guidance

Oct 27, 2021 07:00 am ET

Stevanato Group to Report Third Quarter Financial Results on November 9

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the third quarter of fiscal 2021 on Tuesday, November 9, 2021 at 6:30 a.m. Eastern Time (12:30 CET).

Oct 19, 2021 09:30 am ET

Stevanato Group Wins Pharma Innovation Award For AI-ready Vision Robot Unit (VRU)

Stevanato Group (NYSE:STVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, has been recognized as a winner of Pharma Manufacturing magazine’s 2021 Pharma Innovation Award for its AI-ready Vision Robot Unit (VRU) - a robotic human-like inspection unit.

Oct 04, 2021 10:02 am ET

Stevanato Group Initiates Construction on New U.S. Facility

Stevanato Group (NYSE:STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that it will begin construction on its new U.S. facility in Fishers, Indiana, this month. The site, expected to be operational in 2023, is expected to enable Stevanato Group to be in closer proximity to its North America pharmaceutical customers and to provide an additional supply source for its mission critical products to serve customers better.

Aug 19, 2021 06:30 am ET

Stevanato Group Announces Second Quarter 2021 Financial Results

Aug 17, 2021 08:49 am ET

Stevanato Group Announces Underwriters’ Partial Exercise of Over-Allotment Option

Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that the underwriters of the Company’s recently completed initial public offering of its ordinary shares have exercised in part their option to acquire an additional 1,018,280 ordinary shares at $21 a share.

Aug 11, 2021 07:54 am ET

Stevanato Group to Report Second Quarter Financial Results on August 19

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the second quarter of fiscal year 2021 on Thursday, August 19, 2021.

Jul 16, 2021 12:07 pm ET

Stevanato Group Celebrates Initial Public Offering and First Day of Public Trading on New York Stock Exchange (NYSE)

Stevanato Group S.p.A. (the “Company”) today celebrates its debut on the New York Stock Exchange under the ticker symbol “STVN.” Founded by Giovanni Stevanato in 1949, the Company is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

Jul 15, 2021 06:41 pm ET

Stevanato Group Announces Pricing of Initial Public Offering

Stevanato Group S.p.A. (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its initial public offering of 32,000,000 of its ordinary shares at a price of $21 per share.

Ad blocking detected

Stevanato Group SpA (N:STVN)

Business Focus: Medical Equipment, Supplies & Distribution